Safety Reading Notes

Read safety context beside the research guide.

The LEA source set includes safety-context rows around LEA biology, metabolism, physiology, or safety-relevant mechanisms: mechanistic or pharmacological. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 35203453

Evidence class: mechanistic or pharmacological

PubMed For Dummies Article

LEA Evidence Review: the long-form source walk-through

Quick read
  • LEA currently has 14 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 35203453
  • The evidence classes most visible in the row language are mechanistic or pharmacological (5), insufficient (4), preclinical (3), and preliminary human (2). PMID 24677570
  • The study-design language most visible in the row language is Animal study (6), Narrative or expert review (2), and Cellular or in vitro study (2). PMID 29778785
  • The repeated topics are LEA biology, metabolism, physiology, or safety-relevant mechanisms (14), which tells the reader where to start opening PubMed and DOI links. PMID 24681513

Start with the research question

LEA is built from 14 source-backed evidence row(s) and 14 research source(s). The current evidence classes read as mechanistic or pharmacological (5), insufficient (4), preclinical (3), and preliminary human (2), and the study-design language most often reads as Animal study (6), Narrative or expert review (2), and Cellular or in vitro study (2). PMID 35203453

The row-level question is not simply whether LEA is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are LEA biology, metabolism, physiology, or safety-relevant mechanisms (14). PMID 24677570

Human evidence 2 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 37298321

Preclinical evidence 3 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 36733808

Mechanistic evidence 5 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 18316044

Limits and uncertainty 4 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 21573043

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 30070030

Where this page has the most source density

The largest bucket surfaced for this page is LEA biology, metabolism, physiology, or safety-relevant mechanisms: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is LEA biology, metabolism, physiology, or safety-relevant mechanisms: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 35203453

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 24677570

Bucket chapters: what the literature is circling

LEA biology, metabolism, physiology, or safety-relevant mechanisms: mechanistic or pharmacological

5 research sources 5 rows (1177, 1179, 1183, 1184, 1185) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on LEA biology, metabolism, physiology, or safety-relevant mechanisms: mechanistic or pharmacological. It currently draws from 5 research source(s), so the exact study type matters. PMID 35203453

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 35203453

  • Evidence row 1177

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vit... PMID 35203453

  • Evidence row 1179

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro s... PMID 21573043

LEA biology, metabolism, physiology, or safety-relevant mechanisms: insufficient

4 research sources 4 rows (1172, 1174, 1180, 1181) Evidence class: insufficient

This bucket summarizes source-backed rows focused on LEA biology, metabolism, physiology, or safety-relevant mechanisms: insufficient. It currently draws from 4 research source(s), so the exact study type matters. PMID 24677570

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 24677570

  • Evidence row 1172

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome meas... PMID 24677570

  • Evidence row 1174

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: LEA biology, metabolism, physiology, or safety-relevan... PMID 24681513

LEA biology, metabolism, physiology, or safety-relevant mechanisms: preclinical

3 research sources 3 rows (1176, 1178, 1182) Evidence class: preclinical

This bucket summarizes source-backed rows focused on LEA biology, metabolism, physiology, or safety-relevant mechanisms: preclinical. It currently draws from 3 research source(s), so the exact study type matters. PMID 36733808

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 36733808

  • Evidence row 1176

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism,... PMID 36733808

  • Evidence row 1178

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: LEA bi... PMID 18316044

LEA biology, metabolism, physiology, or safety-relevant mechanisms: preliminary human

2 research sources 2 rows (1173, 1175) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on LEA biology, metabolism, physiology, or safety-relevant mechanisms: preliminary human. It currently draws from 2 research source(s), so the exact study type matters. PMID 29778785

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 29778785

  • Evidence row 1173

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, phy... PMID 29778785

  • Evidence row 1175

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, phy... PMID 37298321

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (2 row(s)), mechanistic evidence (5 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 35203453

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 24677570

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 11463796
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 36316276
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 26707833

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 35203453

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 24677570

Source-reading checklist for LEA

  1. Open the linked PubMed or DOI record. PMID 16081411
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 17574742
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 35203453
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 24677570
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 29778785

Source Notes

LEA source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1172

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 24677570

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Classical endocannabinoid-like compounds and their regulation by nutrients.
  2. Evidence row 1173

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 29778785

    Evidence class: preliminary human. Source: Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males.
  3. Evidence row 1174

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 24681513

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat.
  4. Evidence row 1175

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 37298321

    Evidence class: preliminary human. Source: Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder.
  5. Evidence row 1176

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 36733808

    Evidence class: preclinical; Study design: Animal study. Source: Dietary oleic acid contributes to the regulation of food intake through the synthesis of intestinal oleoylethanolamide.
  6. Evidence row 1177

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 35203453

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study.
  7. Evidence row 1178

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 18316044

    Evidence class: preclinical; Study design: Animal study. Source: Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine.
  8. Evidence row 1179

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 21573043

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine.
  9. Evidence row 1180

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 30070030

    Evidence class: insufficient. Source: Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight.
  10. Evidence row 1181

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 11463796

    Evidence class: insufficient; Study design: Animal study. Source: Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance.
  11. Evidence row 1182

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 36316276

    Evidence class: preclinical; Study design: Animal study. Source: Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome.
  12. Evidence row 1183

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 26707833

    Evidence class: mechanistic or pharmacological. Source: Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease.
  13. Evidence row 1184

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 16081411

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists.
  14. Evidence row 1185

    LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 17574742

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol.